Home HOME Neoplasma 2019 Neoplasma Vol.66, No.3, p.459-469, 2019

Journal info

6 times a year.
Founded: 1954
ISSN 0028-2685
ISSN 1338-4317 (online)

Published in English

Editorial Info
Abstracted and Indexed
Submission Guidelines

Select Journal

Webshop Cart

Your Cart is currently empty.

Info: Your browser does not accept cookies. To put products into your cart and purchase them you need to enable cookies.

Neoplasma Vol.66, No.3, p.459-469, 2019

Title: Prognostic risk model construction and molecular marker identification in glioblastoma multiforme based on mRNA/microRNA/long non-coding RNA analysis using random survival forest method
Author: H. Wang, D. Liu, J. Yang

Abstract: We aim to identify novel molecular signatures for prognosis prediction in glioblastoma multiforme (GBM). The expression and microarray data of GBM were downloaded from The Cancer Genome Atlas (TCGA) and the Gene Expression Omnibus (GEO). Differentially expressed mRNAs, microRNAs (miRNAs) and long non-coding RNAs (lncRNAs) between GBM and normal samples were identified by differential expression analysis using Bayesian T-test. Functional enrichment analysis was performed to identify GBM associated functions and pathways. A subset of signature mRNAs was selected from differentially expressed mRNAs and used to build a risk model for GBM using random survival forest (RSF) method. The performance of the model in prognosis prediction was validated using an independent validation dataset. A competing endogenous RNA (ceRNA) network was then constructed and key prognostic markers were identified from the network by survival analysis. In total, 905 mRNAs, 24 miRNAs and 403 lncRNAs were identified to be differentially expressed between GBM and normal samples. Functional and pathway items such as p53 signaling and PI3K/Akt signaling were significantly enriched by differentially expressed mRNAs. The RSF risk model showed a high performance in prognosis prediction for both training and validation dataset. The ceRNA network provided a comprehensive view of the interplays between differentially expressed mRNAs, miRNAs and lncRNAs. Among the ceRNA network, p21 (RAC1) activated kinase 1 (PAK1) and synaptic vesicle glycoprotein 2B (SV2B) were identified as key prognosis associated markers. The RSF risk model and key prognostic markers may contribute to GBM diagnosis in future clinical practice.

Keywords: glioblastoma multiforme, ceRNA, prognosis, biomarkers
Published online: 28-May-2019
Year: 2019, Volume: 66, Issue: 3 Page From: 459, Page To: 469

download file

© AEPress s.r.o
Copyright notice: For any permission to reproduce, archive or otherwise use the documents in the ELiS, please contact AEP.